The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. METHODS: The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel (group C). The studies were amended to include a joint analysis comparing groups 1 and A (the control group) with groups 2 and C (the trastuzumab group). Group B was excluded because trastuzumab was not given concurrently with paclitaxel. RESULTS: By March 15, 2005, 394 events (recurrent, second primary cancer, or death before recurrence) had been reported, triggering the first scheduled interim analysis. Of these, 133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48; P<0.0001). This result crossed the early stopping boundary. The absolute difference in disease-free survival between the trastuzumab group and the control group was 12 percent at three years. Trastuzumab therapy was associated with a 33 percent reduction in the risk of death (P=0.015). The three-year cumulative incidence of class III or IV congestive heart failure or death from cardiac causes in the trastuzumab group was 4.1 percent in trial B-31 and 2.9 percent in trial N9831. CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Self-citationForest plots: trying to see the wood and the trees
Lewis, S., & Clarke, M. (2001) · BMJ · doi:10.1136/bmj.322.7300.1479 · Cited by 763
CNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A. J., Danson, S., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R. S., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 385
Research works printed but not linked: 2
- Albain KS, 2002, Proc Am Soc Clin Oncol, 21, 37A abstract
- Ewer MS, 2002, Proc Am Soc Clin Oncol, 21, 123A
Cited by
Items 201–300 of 319
Mehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D. C., & Radisky, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.1932 · Cited by 368
Krop, I. E., LoRusso, P., Miller, K. D., Modi, S., Yardley, D., Rodriguez, G., Guardino, E., Lu, M., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366
Inflammatory Breast Cancer: The Disease, the Biology, the Treatment
Robertson, F. M., Bondy, M., Yang, W., Yamauchi, H., Wiggins, S., Kamrudin, S., Krishnamurthy, S., Le-Petross, H., Bidaut, L., Player, A. N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20082 · Cited by 366
Guarneri, V., Lenihan, D. J., Valero, V., Durand, J.-B., Broglio, K., Hess, K. R., Michaud, L. B., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Esteva, F. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9551 · Cited by 361
Guarneri, V., Frassoldati, A., Bottini, A., Cagossi, K., Bisagni, G., Sarti, S., Ravaioli, A., Cavanna, L., Giardina, G., Musolino, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0823 · Cited by 360
Bradley, R., Braybrooke, J., Gray, R., Hills, R., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00288-6 · Cited by 354
Self-citationHow much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Chen, J., Long, J. B., Hurria, A., Owusu, C., Steingart, R. M., & Gross, C. P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.068 · Cited by 352
Boku, N. (2014) · Gastric Cancer · doi:10.1007/s10120-013-0252-z · Cited by 351
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
Coley, H. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.007 · Cited by 351
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial
Heijnen, E. M., Eijkemans, M. J., De Klerk, C., Polinder, S., Beckers, N. G., Klinkert, E. R., Broekmans, F. J., Passchier, J., Te Velde, E. R., Macklon, N. S., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60360-2 · Cited by 349
Van Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Geoghegan, C., Hillner, B. E., Theriault, R. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5209 · Cited by 342
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
Prowell, T. M., & Pazdur, R. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1205737 · Cited by 342
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W. C., Arbushites, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0590 · Cited by 338
Wildiers, H., Kunkler, I., Biganzoli, L., Fracheboud, J., Vlastos, G., Bernard-Marty, C., Hurria, A., Extermann, M., Girre, V., Brain, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70378-9 · Cited by 338
Saadatmand, S., Bretveld, R., Siesling, S., & Tilanus-Linthorst, M. M. A. (2015) · BMJ · doi:10.1136/bmj.h4901 · Cited by 337
Pivot, X., Romieu, G., Debled, M., Pierga, J.-Y., Kerbrat, P., Bachelot, T., Lortholary, A., Espié, M., Fumoleau, P., Serin, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70225-0 · Cited by 337
Sahin, Ö., Fröhlich, H., Löbke, C., Korf, U., Burmester, S., Majety, M., Mattern, J., Schupp, I., Chaouiya, C., Thieffry, D., et al. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-1 · Cited by 335
Trastuzumab: triumphs and tribulations
Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 334
Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002661 · Cited by 334
Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 334
Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain
Palmieri, D., Bronder, J. L., Herring, J. M., Yoneda, T., Weil, R. J., Stark, A. M., Kurek, R., Vega-Valle, E., Feigenbaum, L., Halverson, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3316 · Cited by 333
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
Metastasis: a therapeutic target for cancer
Steeg, P. S., & Theodorescu, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1066 · Cited by 332
Mittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1735 · Cited by 330
“Currently, our practice is to administer trastuzumab postoperatively to complete 1 year of therapy based on data from the multicenter adjuvant trials (7, 8).”
BackgroundMethodSeol, H., Lee, H. J., Choi, Y., Lee, H. E., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., & Park, S. Y. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.36 · Cited by 330
Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy
King, T. A., Sakr, R., Patil, S., Gurevich, I., Stempel, M., Sampson, M., & Morrow, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4041 · Cited by 330
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3071 · Cited by 326
Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7582730 · Cited by 325
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Schuh, A., Becq, J., Humphray, S., Alexa, A., Burns, A., Clifford, R., Feller, S. M., Grocock, R., Henderson, S., Khrebtukova, I., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433540 · Cited by 322
Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R., & Abdulkarim, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0250 · Cited by 321
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Sachdev, D., & Yee, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0080 · Cited by 320
Serum autoantibodies as biomarkers for early cancer detection
Tan, H. T., Low, J., Lim, S. G., & Chung, M. C. M. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07396.x · Cited by 315
Heneghan, H. M., Miller, N., Kelly, R., Newell, J., & Kerin, M. J. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0103 · Cited by 315
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy
Sachdev, D., & Yee, D. (2008) · AACR Education book · doi:10.1158/aacr.edb-mct-06-0080 · Cited by 314
Wang, A. Z., Bagalkot, V., Vasilliou, C. C., Gu, F., Alexis, F., Zhang, L., Shaikh, M., Yuet, K., Cima, M. J., Langer, R., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200800091 · Cited by 312
Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
The New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 307
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Self-citationTrastuzumab in the Treatment of Breast Cancer
Hortobagyi, G. N. (2005) · New England Journal of Medicine · doi:10.1056/nejme058196 · Cited by 306
Patt, D. A., & Giordano, S. H. (2007) · Breast Diseases: A Year Book Quarterly · doi:10.1016/s1043-321x(07)80352-3 · Cited by 305
Cameron, D., Casey, M., Oliva, C., Newstat, B., Imwalle, B., & Geyer, C. E. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0181 · Cited by 304
Self-citationChia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
New Targetable Oncogenes in Non–Small-Cell Lung Cancer
Oxnard, G. R., Binder, A., & Jänne, P. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9829 · Cited by 299
Spielmann, M., Roché, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0946 · Cited by 298
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda, N., Kodaira, M., Yamamoto, H., Yunokawa, M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118612 · Cited by 294
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M.-L., Simcock, R., Rea, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30650-6 · Cited by 286
PTEN, PIK3CA, p-AKT, and p-p70S6K Status
Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Morgan, T., Koreckij, T., & Corey, E. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787580999 · Cited by 283
Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn216 · Cited by 283
Hanna, W. M., Rüschoff, J., Bilous, M., Coudry, R. A., Dowsett, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.103 · Cited by 281
Triple-negative/basal-like breast cancer: review
Rakha, E. A., & Ellis, I. O. (2009) · Pathology · doi:10.1080/00313020802563510 · Cited by 281
Progress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Guglin, M., Krischer, J., Tamura, R., Fink, A., Bello-Matricaria, L., McCaskill-Stevens, W., & Munster, P. N. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.495 · Cited by 281
The Treatment of Breast Cancer
(1974) · Springer eBooks · doi:10.1007/978-94-011-7152-6 · Cited by 280
Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X., Botero, M. F., Healy, N. A., Hilsenbeck, S. G., Phillips, G. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3067 · Cited by 280
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Johnson, K. S., Conant, E. F., & Soo, M. S. (2021) · Journal of Breast Imaging · doi:10.1093/jbi/wbaa110 · Cited by 280
Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer
Gagliato, D. D. M., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L., Giordano, S. H., Valero, V., Hortobagyi, G. N., & Chavez-MacGregor, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7693 · Cited by 279
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Ezaz, G., Long, J. B., Gross, C. P., & Chen, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000472 · Cited by 276
Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment
Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018) · Radiology · doi:10.1148/radiol.2018172171 · Cited by 275
Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutierrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone, K. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1005 · Cited by 271
Biofunctionalized targeted nanoparticles for therapeutic applications
Wang, A. Z., Gu, F., Zhang, L., Chan, J. M., Radovic-Moreno, A., Shaikh, M. R., & Farokhzad, O. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1063 · Cited by 270
Insights from transgenic mouse models of ERBB2-induced breast cancer
Ursini-Siegel, J., Schade, B., Cardiff, R. D., & Muller, W. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2127 · Cited by 269
Targeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
Dowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 267
Implications of micro-RNA profiling for cancer diagnosis
Cummins, J. M., & Velculescu, V. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209914 · Cited by 266
Positive Psychology in Cancer Care: Bad Science, Exaggerated Claims, and Unproven Medicine
Coyne, J. C., & Tennen, H. (2010) · Annals of Behavioral Medicine · doi:10.1007/s12160-009-9154-z · Cited by 266
Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris III, H. A., LoRusso, P. M., Yi, J.-H., Saad, O., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1817-3 · Cited by 262
Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis
Tang, J., Kong, D., Cui, Q., Wang, K., Zhang, D., Gong, Y., & Wu, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00374 · Cited by 262
Benson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 261
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., Chen, B., Ingle, J. N., Dakhil, S. R., Zujewski, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7045 · Cited by 255
Self-citationGoss, P. E., Ingle, J. N., Pritchard, K. I., Ellis, M. J., Sledge, G. W., Budd, G. T., Rabaglio, M., Ansari, R. H., Johnson, D. B., Tozer, R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7805 · Cited by 255
Self-citationNCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Vahid, B., & Marik, P. E. (2008) · Chest · doi:10.1378/chest.07-0851 · Cited by 254
Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252
“The HER2 monoclonal antibody, trastuzumab, has been approved as adjuvant treatment for patients with breast cancer with HER2 overexpression, reducing both the recurrence rate and mortality.(4) Lapatinib, a reversible dual kinase inhibitor against EGFR and HER2,(5) has activity in patients with HER2 overexpression when…”
BackgroundHarris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Harris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5689 · Cited by 206
Mitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., Lesko, S. M., Brogi, E., & Jones, F. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0295 · Cited by 204
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0900 · Cited by 193
Wang, J.-H., Forterre, A. V., Zhao, J., Frimannsson, D. O., Delcayre, A., Antes, T. J., Efron, B., Jeffrey, S. S., Pegram, M. D., & Matin, A. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0827 · Cited by 181
Cardiovascular disease after cancer therapy
Aleman, B. M. P., Moser, E. C., Nuver, J., Suter, T. M., Maraldo, M. V., Specht, L., Vrieling, C., & Darby, S. C. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.002 · Cited by 168
Metadata
- Authors
- Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Ingle, J. N., & Wolmark, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-10-20
- Volume
- 353
- Issue
- 16
- Pages
- 1673-1684
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2146384083
- Cited by
- 5,356
- References
- 12
- FWCI
- 148.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.